2015;100:2136 45. 15. Thourani VH, Forcillo J, Beohar N, et al. Impact of preoperative chronic kidney disease in 2,531 high-risk and inoperable patients undergoing transcatheter aortic valve replacement in the PARTNER Trial. Ann Thorac Surg. 2016;102:1172 80. 16. Puri R, Iung B, Cohen DJ, et al. TAVI or no TAVI: identifying patients un- likely to benefit from transcatheter aortic valve implantation. Eur Heart J. 2016;37:2217 25. 17. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64:172 81. 18. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mi- tral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64:182 92. 19. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307 18. 20. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgi- cal mortality in the United States. N Engl J Med. 2002;346:1128 37. 21. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural volume and out- comes for transcatheter aortic-valve replacement. N Engl J Med. 2019;380:2541 50. 22. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcath- eter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol. 2017;70:29 41. 23. Russo MJ, McCabe JM, Thourani VH, et al. Case volume and outcomes af- ter TAVR with balloon-expandable prostheses: insights from TVT registry. J Am Coll Cardiol. 2019;73:427 40. 24. Bolling SF, Li S, O Brien SM, et al. Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg. 2010;90:1904 11. 25. Badhwar V, Ofenloch JC, Rovin JD, et al. 